An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.
- 06 Feb 2017 Planned primary completion date changed from 8 Jan 2018 to 8 Jan 2019.
- 08 Feb 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov.